Pathophysiology and medical management of systemic hypertension in pregnancy

Cardiology in Review

Volumn 13, Issue 6, 2005, Pages 274-284

  Frishman, William H ^a,d   Schlocker, Stacy J ^b   Awad, Ketti ^c   Tejani, Nergesh ^a  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b SCRIPPS MERCY HOSPITAL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Drug prevention; Drug therapy; Hypertension; Preeclampsia; Pregnancy

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIAZOXIDE; DIURETIC AGENT; DOXAZOSIN; HYDRALAZINE; ISRADIPINE; LABETALOL; MAGNESIUM SULFATE; METHYLDOPA; METOPROLOL; NIFEDIPINE; NITROPRUSSIDE SODIUM; PHENOXYBENZAMINE; PRAZOSIN; TERAZOSIN; VASODILATOR AGENT;

BRADYCARDIA; CYANIDE POISONING; DELIVERY; DISEASE CLASSIFICATION; DIZZINESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FLUID RETENTION; FLUSHING; HEADACHE; HEART PALPITATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOVOLEMIA; INTRAUTERINE GROWTH RETARDATION; LABOR INHIBITION; LOW DRUG DOSE; MATERNAL HYPERTENSION; NAUSEA; NEONATAL RESPIRATORY DISTRESS SYNDROME; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; PREECLAMPSIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SKIN TINGLING; SOLUTIO PLACENTAE; TACHYCARDIA; THROMBOCYTOPENIA; VOMITING;

ANTIHYPERTENSIVE AGENTS; CHRONIC DISEASE; FEMALE; HUMANS; HYPERTENSION; HYPERTENSION, PREGNANCY-INDUCED; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; UNITED STATES;

EID: 27644439281     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.crd.0000137738.16166.cc     Document Type: Review

References (101)

1. Seely EW, Lindheimer MD. Pathophysiology of preeclampsia. In: Izzi JL Jr, Black HR, eds. Hypertension Primer, 3rd ed. Dallas: American Heart Association; 2003:160-163.
2. American College of Obstetricians and Gynecologists, technical bulletin No. 219. Hypertension in Pregnancy. Int J Gynecol Obstet. 1996; 53:175-183.
3. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183:S1-S21.
4. Barron WM, Lindheimer MD. Management of hypertension during pregnancy. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management, 2nd ed. New York: Raven Press Ltd; 1995:2427-2450.
5. American College of Obstetricians and Gynecologists, practice bulletin No. 33. Diagnosis and management of preeclampsia and eclampsia. Int J Gynaecol Obstet. 2002;77:67-75.
6. Sibai BM. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol. 1990;163:1049-1055.
7. Sibai BM, Ramadan MK, Usta I, et al. Maternal morbidity and mortality in 442 pregnancies with hemolysis, elevated liver enzymes, and low platelets (HELLP syndrome). Am J Obstet Gynecol. 1993;169: 1000-1006.
8. Roberts JM, Redman CWG. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341:1447-1454.
9. Cooper DW. Genetics of pre-eclampsia. Hypertension in Pregnancy. 1993;12:1-23.
10. Morgan T, Ward K. New insights into the genetics of preeclampsia. Semin Perinatol 1999;23:14-23.
11. Savvidou MD, Hingorani AD, Tsikas D, et al. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003;361:1511-1517.
12. Thadhani R, Ecker JL, Mutter WP, et al. Insulin resistance and alterations in angiogenesis. Additive insults that may lead to preeclampsia. Hypertension. 2004;43:988-992.
13. Levine RJ, Maynard SE, Qian C, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672-683.
14. Solomon CG, Seely EW. Preeclampsia-searching for the cause. N Engl J Med. 2004;350:641-642.
15. Maynard SE, Min J-Y, Merchan J, et al. Excess placental soluble fins-like tyrosine kinase 1 (sFlt) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
16. Wallukat G, Homuth V, Fischer T, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest. 1999;103:945-52.
17. Mills J, DerSimonian R, Raymond E, et al. Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study. JAMA. 1999;282:356-362.
18. McCarthy AL, Woolfson RG, Raju SK, et al. Abnormal endothelial cell function of resistance arteries from women with preeclampsia. Am J Obstet Gynecol. 1993;168:1323-1330.
19. Pascoal IF, Lindneimer MD, Nalbantian-Brandt C, et al. Preeclampsia selectively impairs endothelium-dependent relaxation and leads to oscillatory activity in small omental arteries. J Clin Invest. 1998;101: 464-470.
20. Lindheimer MD, Katz AI. The renal response to pregnancy. In: Brenner BM, Rector FC, eds. The Kidney: Physiology and Pathophysiology, 2nd ed. New York: Raven Press; 1992:1762-1815.
21. Sibai BM. Treatment of hypertension in pregnant women. N Engl J Med. 1996;335:257-265.
22. August P, Marcaccio B, Gerter JM, et al. Abnormal (1,25)dihydroxyvitamin D metabolism in preeclampsia. Am J Obstet Gynecol. 1992;4: 1295-1299.
23. Seely EW, Wood RJ, Brown EM, et al. Low serum ionized calcium and abnormal calciotropic hormone levels in preeclampsia. J Clin Endocrinol Metab. 1992;74:1436-1440.
24. Sheehan HL, Lynch JB. Pathology of Toxaemia of Pregnancy. London: Churchill, Livingstone; 1973.
25. Witlin AG, Sibai BM. Hypertension in pregnancy: current concepts of preeclampsia. Ann Rev Med. 1997;48:115-127.
26. Shah DM, Reed G. Parameters associated with adverse perinatal outcome in hypertensive pregnancies. J Hum Hypertens. 1996;10:511-515.
27. Izumi A, Minakami H, Kuwata T, et al. Calcium-to-creatinine ratio in spot urine samples in early pregnancy and its relation to the development of preeclampsia. Metab Clin Exp. 1997;46:1107-1108.
28. Lim KH, Friedman SSA, Ecker JL, et al. The clinical utility of serum uric acid measurements in hypertensive diseases of pregnancy. Am J Obstet Gynecol. 1998;178:1067-1071.
29. Masse J, Forest JC, Moutquin JM, et al. A prospective study of several potential biologic markers for early prediction of the development of preeclampsia. Am J Obstet Gynecol. 1993;169:501-508.
30. Sibai BM, Lindheimer M, Hauth J, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. N Engl J Med. 1998;339:667-671.
31. Sibai BM. Diagnosis and management of gestational hypertension and pre-eclampsia. Obstet Gynecol. 2003;102:181-192.
32. Lewis R, Sibai BM. Recent advances in the management of preeclampsia. J Matern Fetal Neonatal Med. 1997;6:6-15.
33. Punvar M, Kulkarni H, Motghare V, et al. Calcium supplementation and prevention of pregnancy induced hypertension. J Obstet Gynaecol Res. 1996;22:425-430.
34. Sanchez-Ramos L, Briones DK, Kaunitz AM, et al. Prevention of pregnancy-induced hypertension by calcium supplementation in angiotensin 11-sensitive patients. Obstet Gynecol. 1994;84:349-353.
35. Belizan JM, Villar J, Gonzalez L, et al. Calcium supplementation to prevent hypertensive disorders of pregnancy. N Engl J Med. 1991;325: 1399-1405.
36. Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med. 1997;337:69-76.
37. Dekker GA. The pharmacological prevention of preeclampsia. Balliere's Clinical Obstetrics and Gynecology. 1995;9:509-528.
38. Louden KA, Pipkin FB, Heptinstall S, et al. Neonatal platelet reactivity and serum thromboxane B2 production in whole blood: the effect of maternal low dose aspirin. Br J Obstet Gynaecol. 1994;101:203-208.
39. Dekker GA, Sibai BM. Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. Am J Obstet Gynecol. 1993;168:214-227.
40. Sibai BM, Caritis SN, Thorn E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. N Engl J Med. 1993;329:1213-1218.
41. CLASP Collaborative Group. CLASP: a randomized trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9364 pregnant women. Lancet. 1994;343:619-629.
42. ECPPA Collaborative Group. ECPPA: randomised trial of low-dose aspirin for the prevention of maternal and fetal complications in high risk pregnant women. Br J Obstet Gynaecol. 1996;103:39-47.
43. Viinikka L, Hartikainen-Sorri AL, Lumme R, et al. Low dose aspirin in hypertensive pregnant women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. Br J Obstet Gynaecol. 1993;100:809-815.
44. Italian Study of Aspirin in Pregnancy. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension. Lancet. 1993;341;396-400.
45. Hauth JC, Goldenberg RL, Parker R, et al. Low dose aspirin to prevent preeclampsia. Am J Obstet Gynecol. 1993;168:1083-1093.
46. Coomarsamy A, Honest H, Papaioannou S, et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol. 2003;101:1319-1332.
47. Hermida RC, Ayala DE, Iglesias M. Administration time-dependent influence of aspirin on blood pressure in pregnant women. Hypertension. 2003;41:651-656.
48. Seligman SP, Buyon JP, Clancy RM, et al. The role of nitric oxide in the pathogenesis of preeclampsia. Am J Obstet Gynecol. 1994;171: 944-948.
49. Helmbrecht GD, Farhat MY, Lochbaum L, et al. L-Arginine reverses the adverse pregnancy changes induced by nitric oxide synthase inhibition in the rat. Am J Obstet Gynecol. 1996;175:800-805.
50. Shinyama H, Akira T, Uchida T, et al. Antithrombin III prevents renal dysfunction and hypertension induced by enhanced intravascular coagulation in pregnant rats: pharmacological confirmation of the benefits of treatment with antithrombin III in preeclampsia. J Cardiovasc Pharmacol. 1996;27:702-711.
51. Roberts JM, Hubel CA. Is oxidative stress the link in the two-stage model of preeclampsia? Lancet. 1999;354:788-789.
52. Roberts JM, Pearson G, Cutler J, et al. Summary of the NHLBI working group on research on hypertension during pregnancy. Hypertension. 2003;41:437-445.
53. Gulmezoglu AM, Hofmeyr GJ, Oosthuisen MM. Antioxidants in the treatment of severe PE: an explanatory randomized controlled trial. Br J Obstet Gynecol. 1997;104:689-696.
54. Chappell LC, Seed PT, Briley AL, et al. Effect of antioxidants on the occurrence of preeeclampsia in women at increased risk: a randomised trial. Lancet. 1999;354:810-816.
55. Chappell LC, Seed PT, Kelly FJ, et al. Vitamin C and E supplementation in women at risk of preeclampsia is associated with changes in indices of oxidative stress and placental function. Am J Obstet Gynecol. 2002;187:777-784.
56. Von Dadelszen P, Ornstein MP, Bull SB, et al. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. Lancet. 2000;355:87-92.
57. Sibai BM, Gonzalez AR, Mabie WC, et al. A comparison of labetalol plus hospitalization versus hospitalization alone in management of preeclampsia remote from term. Obstet Gynecol. 1987;70:323-327.
58. Pickles CJ, Broughton-Pipkin F, Symonds EM. A randomized placebo-controlled trial of labetalol in the treatment of mild to moderate pregnancy-induced hypertension. Br J Obstet Gynaecol. 1992;99:964-968.
59. Hsueh WA. Preeclampsia and hypertension in pregnancy. Curr Ther Endocrinol Metab. 1997;6:324-327.
60. Duley L, Henderson-Smart DJ. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2000;2: CD001449.
61. Bhorat IE, Naidoo DP, Rout CC, et al. Malignant ventricular arrhythmias in eclampsia: a comparison of labetalol with dihydralazine. Am J Obstet Gynecol. 1993;168:1292-1296.
62. Walker JJ, Greer I, Calder AA. Treatment of acute pregnancy-related hypertension: labetalol and hydralazine compared. Postgrad Med. 1983;59(suppl 3):168-170.
63. Mansoor GA, Frishman WH. Comprehensive management of hypertensive emergencies and urgencies. Heart Dis. 2002;4:358-371.
64. Mabie WC, Gonzalez AR, Sibai BM, et al. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol. 1987;70:328-333.
65. Lewis R, Sibai BM. The use of calcium-channel blockers in pregnancy. New Horizons. 1996;4:115-122.
66. Aali BS, Nejad SS. Nifedipine or hydralazine as a first-line agent to control hypertension in severe preeclampsia. Acta Obstel Gynecol Scand. 2002;81:25-30.
67. Borghi C, Esposti DD, Cassani A, et al. The treatment of hypertension in pregnancy. J Hypertens. 2002;20(suppl 2):S52-S56.
68. Scardo JA, Vermillion ST, Hogg BB, et al. Hemodynamic effects of oral nifedipine in preeclamptic hypertensive emergencies. Am J Obstet Gynecol. 1996;175:336-340.
69. Bennert TL, Stubblefield PG. Massive vulvar edema complicating tocolysis in a patient with twins. A case report. J Reprod Med. 1996;41:121-124.
70. Ben-Ami M, Giladi Y, Shalev E. The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade. Br J Obstet Gynaecol. 1994;101:262-263.
71. Waisman GD, Mayorga LM, Camera MI, et al. Magnesium plus nifedipine: potentiation of hypotensive effect in preeclampsia? Am J Obstet Gynecol. 1988;159:308-309.
72. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002; 100:369-377.
73. Sibai BM. Diagnosis and management of chronic hypertension in pregnancy. Obstet Gynecol. 1991;78:451-461.
74. Ales K, Charlson ME. The prediction of adverse outcomes in antepartum hypertension. Clin Exp Hypertens Pregnancy. 1989;B8:95-112.
75. Sibai BM, Abdella TN, Anderson GD. Pregnancy outcomes in 211 patients with mild chronic hypertension. Obstet Gynecol. 1983;61:571-576.
76. Varma TR. Serum uric acid levels as an index of fetal prognosis in pregnancies complicated by preexisting hypertension and preeclampsia of pregnancy. Intl J Gynaecol Obstet. 1987;25:35-40.
77. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Lancet. 1990;335:827-838.
78. Sibai BM, Anderson GD. Pregnancy outcome of intensive therapy in severe hypertension in first trimester. Obstet Gynecol. 1986;67:517-522.
79. Sibai BM, Mabie WC, Shamsa F, et al. A comparison of no medication versus methyldopa or labetalol in chronic hypertension during pregnancy. Am J Obstet Gynecol. 1990;162:960-967.
80. Chobanian AV, Bakris GL, Block HR, et al. ., for the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Commission on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 Report. JAMA. 2003;289:2560-2572.
81. Lindheimer MD. Preeclampsia-eclampsia 1996: preventable? Have disputes on its treatment been resolved? Curr Opin Nephrol Hypertens. 1996;5:452-458.
82. Cockburn J, Moar VA, Ounsted M, et al. Final report of study on hypertension during pregnancy: the effects of specific treatment on the growth and development of the children. Lancet. 1982;1:647-649.
83. Ngo A, Frishman WH, Elkayam M. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmaco-therapeutics. New York: McGraw Hill; 1997:1309-1345.
84. Qasqas SA, McPherson C, Frishman WH, et al. Cardiovascular pharmacotherapeutic considerations during pregnancy and lactation. Part II. Cardiol Rev. 2004;12:240-261.
85. Gunenc O, Cicek N, Gorkemli H, et al. The effect of methyldopa treatment on uterine, umbilical and fetal middle cerebral artery blood flows in preeclamptic patients. Arch Gynecol Obstet. 2002;266:141-144.
86. Butters L, Kennedy S, Rubin PC. Atenolol in essential hypertension during pregnancy. BMJ. 1990;301:587-589.
87. Lydakis C, Lip GY, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12:541-547.
88. Montan S, Ingermarsson F, Marsal K, et al. Randomized controlled trial of atenolol and pindolol in humen pregnancy: effects on fetal haemodynamics. BMJ. 1992;304:946-949.
89. Plouin PF, Breart G, Maillard F, et al. Comparison of antihypertensive efficacy and perinatal safety of labetalol and methyldopa in the treatment of hypertension in pregnancy: a randomized controlled trial. Br J Obstet Gynecol. 1989;95:868-876.
90. Cruickshank DJ, Robertson AA, Campbell DM, et al. Maternal obstetric outcome measures in a randomized controlled study of labetalol in the treatment of hypertension in pregnancy. Clin Exp Hypertens Pregnancy. 1991;B10:333-344.
91. Jegasothy R, Paranthaman S. Sublingual nifedipine compared with intravenous hydralazine in the acute treatment of severe hypertension in pregnancy, potential for use in rural practice. J Obstet Gynecol Res. 1996;22:21-24.
92. Carbonne B, Jannet D, Touboul C. Nicardipine treatment of hypertension during pregnancy. Obstet Gynecol. 1993;81:908-914.
93. Childress CH, Katz VL. Nifedipine and its indications in obstetrics and gynecology. Obstet Gynecol. 1994;83:616-624.
94. Wide-Swensson DH, Ingemarsson I, Lunell NO, et al. Calcium channel blockade (isradipine) in treatment of hypertension in pregnancy; a randomized placebo-controlled study. Am J Obstet Gynecol. 1995;173: 872-878.
95. Jannet D, Carbonne B, Sebban E, et al. Nicardipine versus metoprolol in the treatment of hypertension during pregnancy: a randomized comparative trial. Obstet Gynecol. 1994;84:354-359.
96. Jayawardana J, Lekamge N. A comparison of nifedipine with methyldopa in pregnancy induced hypertension. Ceylon Med J. 1994;39:87-90.
97. Moretti MM, Fairlie FM, Akl SA, et al. The effect of nifedipine therapy on fetal and placental Doppler waveforms in preeclampsia remote from term. Am J Obstet Gynecol. 1990;163:1844-1848.
98. Sibai BM, Barton JR, Akl SA, et al. A randomized prospective comparison of nifedipine and bed rest versus bed rest alone in the management of preeclampsia remote from term. Am J Obstet Gynecol. 1992;167:879-884.
99. Caruso A, Ferrazzani S, DeCarolis S, et al. The use of nifedipine as first-line hypotensive therapy in gestational hypertension. Minerva Ginecologica. 1994;46:279-284.
100. Lindheimer MD, Akbari A. Hypertension in pregnant women. In: Oparil S, Weber MA, eds. Hypertension: Companion to Brenner & Rector's The Kidney. Philadelphia: WB Saunders Co; 2000:688-701.
101. Taler SJ. Treatment of pregnant hypertensive patients. In: Izzo JL Jr, Black HR, eds. Hypertension Primer, 3rd ed. Dallas: American Heart Association; 2003:491-494.